Top-Rated StocksTop-RatedNASDAQ:AXSM Axsome Therapeutics (AXSM) Stock Price, News & Analysis $93.18 -0.50 (-0.53%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$91.52▼$94.5350-Day Range$78.93▼$95.5652-Week Range$55.02▼$98.40Volume945,658 shsAverage Volume669,595 shsMarket Capitalization$4.43 billionP/E RatioN/ADividend YieldN/APrice Target$124.57 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Axsome Therapeutics alerts: Email Address Axsome Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside33.7% Upside$124.57 Price TargetShort InterestBearish16.15% of Shares Sold ShortDividend StrengthN/ASustainability-1.03Upright™ Environmental ScoreNews Sentiment0.52Based on 23 Articles This WeekInsider TradingSelling Shares$4.02 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($4.72) to ($1.21) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.74 out of 5 starsMedical Sector39th out of 910 stocksPharmaceutical Preparations Industry13th out of 426 stocks 4.5 Analyst's Opinion Consensus RatingAxsome Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 14 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAxsome Therapeutics has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Axsome Therapeutics' stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted16.15% of the outstanding shares of Axsome Therapeutics have been sold short.Short Interest Ratio / Days to CoverAxsome Therapeutics has a short interest ratio ("days to cover") of 11.8, which indicates bearish sentiment.Change versus previous monthShort interest in Axsome Therapeutics has recently decreased by 5.77%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAxsome Therapeutics does not currently pay a dividend.Dividend GrowthAxsome Therapeutics does not have a long track record of dividend growth. Previous Next 4.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAxsome Therapeutics has received a 69.39% net impact score from Upright. The largest positive contribution comes from its "Mental diseases" impact, which is driven by its "Clinical research services for mental health" product. See details.Environmental SustainabilityThe Environmental Impact score for Axsome Therapeutics is -1.03. Previous Next 2.5 News and Social Media Coverage News SentimentAxsome Therapeutics has a news sentiment score of 0.52. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 23 news articles for Axsome Therapeutics this week, compared to 6 articles on an average week.Search Interest9 people have searched for AXSM on MarketBeat in the last 30 days. This is an increase of 125% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Axsome Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Axsome Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,022,488.00 in company stock.Percentage Held by Insiders22.40% of the stock of Axsome Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions81.49% of the stock of Axsome Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Axsome Therapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Axsome Therapeutics are expected to grow in the coming year, from ($4.72) to ($1.21) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Axsome Therapeutics is -14.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Axsome Therapeutics is -14.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAxsome Therapeutics has a P/B Ratio of 42.94. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Axsome Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Timothy SykesTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT about Trump or Biden dropping out of the race…Click here to see a unique election-year trade About Axsome Therapeutics Stock (NASDAQ:AXSM)Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.Read More AXSM Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AXSM Stock News HeadlinesAugust 10, 2024 | insidertrades.comInsider Selling: Axsome Therapeutics, Inc. (NASDAQ:AXSM) COO Sells 47,739 Shares of StockSeptember 7 at 9:54 AM | markets.businessinsider.comAxsome Therapeutics (AXSM) Gets a Buy from Cantor FitzgeraldSeptember 7, 2024 | Golden Crest (Ad)Biden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial independence and security.September 7 at 6:59 AM | americanbankingnews.comCantor Fitzgerald Reaffirms Overweight Rating for Axsome Therapeutics (NASDAQ:AXSM)September 7 at 4:31 AM | americanbankingnews.comAxsome Therapeutics (NASDAQ:AXSM) Stock Rating Reaffirmed by Needham & Company LLCSeptember 6 at 6:57 AM | americanbankingnews.comAxsome Therapeutics (NASDAQ:AXSM) Receives "Buy" Rating from HC WainwrightSeptember 5 at 11:33 PM | msn.comWells Fargo Initiates Coverage of Axsome Therapeutics (AXSM) with Overweight RecommendationSeptember 5 at 11:33 PM | markets.businessinsider.comBuy Rating Affirmed for Axsome Therapeutics on Robust Pipeline and Promising Regulatory ProspectsSeptember 7, 2024 | Golden Crest (Ad)Biden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial independence and security.September 5 at 11:33 PM | markets.businessinsider.comBuy Rating Affirmed for Axsome Therapeutics on Strong Pipeline and Promising Drug TrialsSeptember 5 at 3:01 AM | americanbankingnews.comAxsome Therapeutics (NASDAQ:AXSM) Coverage Initiated at Wells Fargo & CompanySeptember 4 at 12:30 PM | markets.businessinsider.comAxsome Says FDA Acknowledges Resubmission Of NDA For AXS-07 For MigraineSeptember 4 at 7:00 AM | globenewswire.comAxsome Therapeutics Announces FDA Acceptance of NDA Resubmission for AXS-07 for the Acute Treatment of MigraineSeptember 3, 2024 | markets.businessinsider.comStrong Buy Rating for Axsome as Auvelity Sales Surge and Growth Potential SolidifiesAugust 28, 2024 | americanbankingnews.comHC Wainwright Reiterates "Buy" Rating for Axsome Therapeutics (NASDAQ:AXSM)August 28, 2024 | money.usnews.comAxsome Therapeutics IncAugust 27, 2024 | finance.yahoo.comAxsome Therapeutics to Participate in Investor Conferences in SeptemberAugust 22, 2024 | markets.businessinsider.comBuy Rating on Axsome Therapeutics: Legal Wins and Positive Clinical Trial Outlook Secure Market PositionSee More Headlines Receive AXSM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Axsome Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/05/2024Today9/07/2024Next Earnings (Estimated)11/04/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:AXSM CUSIPN/A CIK1579428 Webaxsome.com Phone(212) 332-3241Fax212-320-0245Employees545Year FoundedN/APrice Target and Rating Average Stock Price Target$124.57 High Stock Price Target$180.00 Low Stock Price Target$105.00 Potential Upside/Downside+33.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage14 Analysts Profitability EPS (Most Recent Fiscal Year)($6.38) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-239,240,000.00 Net Margins-105.85% Pretax Margin-106.20% Return on Equity-117.46% Return on Assets-36.39% Debt Debt-to-Equity Ratio1.77 Current Ratio2.48 Quick Ratio2.40 Sales & Book Value Annual Sales$291.49 million Price / Sales15.18 Cash FlowN/A Price / Cash FlowN/A Book Value$2.17 per share Price / Book42.94Miscellaneous Outstanding Shares47,496,000Free Float36,857,000Market Cap$4.43 billion OptionableOptionable Beta1.26 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesDr. Herriot Tabuteau M.D. (Age 56)Founder, Chairman, CEO & President Comp: $1.32MMr. Hunter Murdock Esq. (Age 44)General Counsel & Secretary Comp: $735.39kKey CompetitorsGlobal Blood TherapeuticsNASDAQ:GBTRa PharmaceuticalsNASDAQ:RARXAimmune TherapeuticsNASDAQ:AIMTHarmony BiosciencesNASDAQ:HRMYTaro Pharmaceutical IndustriesNYSE:TAROView All CompetitorsInsiders & InstitutionsClearbridge Investments LLCBought 17,397 shares on 8/27/2024Ownership: 0.225%Dana Investment Advisors Inc.Bought 697 shares on 8/27/2024Ownership: 0.042%Teachers Retirement System of The State of KentuckyBought 1,656 shares on 8/26/2024Ownership: 0.024%Creative PlanningBought 1,149 shares on 8/16/2024Ownership: 0.018%Northwestern Mutual Wealth Management Co.Bought 335 shares on 8/16/2024Ownership: 0.001%View All Insider TransactionsView All Institutional Transactions AXSM Stock Analysis - Frequently Asked Questions How have AXSM shares performed this year? Axsome Therapeutics' stock was trading at $79.59 at the start of the year. Since then, AXSM shares have increased by 17.1% and is now trading at $93.1850. View the best growth stocks for 2024 here. How were Axsome Therapeutics' earnings last quarter? Axsome Therapeutics, Inc. (NASDAQ:AXSM) released its quarterly earnings data on Monday, August, 5th. The company reported ($1.24) earnings per share for the quarter, topping the consensus estimate of ($1.30) by $0.06. The firm had revenue of $87.17 million for the quarter, compared to the consensus estimate of $84.53 million. Axsome Therapeutics had a negative net margin of 105.85% and a negative trailing twelve-month return on equity of 117.46%. When did Axsome Therapeutics IPO? Axsome Therapeutics (AXSM) raised $52 million in an initial public offering (IPO) on Thursday, November 19th 2015. The company issued 4,300,000 shares at a price of $11.00-$13.00 per share. Ladenburg Thalmann and Cantor Fitzgerald & Co. acted as the underwriters for the IPO and Brean Capital was co-manager. Who are Axsome Therapeutics' major shareholders? Axsome Therapeutics' top institutional shareholders include Millennium Management LLC (1.56%), Hood River Capital Management LLC (1.16%), Perceptive Advisors LLC (0.97%) and First Turn Management LLC (0.71%). Insiders that own company stock include Roger Jeffs, Mark Coleman, Mark L Jacobson, Nick Pizzie and Mark E Saad. View institutional ownership trends. How do I buy shares of Axsome Therapeutics? Shares of AXSM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Axsome Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Axsome Therapeutics investors own include Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Dicerna Pharmaceuticals (DRNA), Amarin (AMRN), Sarepta Therapeutics (SRPT), Micron Technology (MU) and Pfizer (PFE). This page (NASDAQ:AXSM) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Axsome Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Axsome Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AXSM Stock Alerts